HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ABCC9
ATP binding cassette subfamily C member 9
Chromosome 12 Β· 12p12.1
NCBI Gene: 10060Ensembl: ENSG00000069431.15HGNC: HGNC:60UniProt: O60706
85PubMed Papers
24Diseases
2Drugs
102Pathogenic Variants
FUNCTIONAL ROLE
ReceptorTransporter
RESEARCH IMPACT
Variant-Rich
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
defense response to viruspotassium channel activityATPase-coupled transmembrane transporter activitytransmembrane transporter bindingHypertrichotic osteochondrodysplasia, Cantu typehypertrichotic osteochondrodysplasia Cantu typedilated cardiomyopathy 1Ointellectual disability and myopathy syndrome
✦AI Summary

ABCC9 encodes SUR2, a regulatory subunit of ATP-sensitive potassium (KATP) channels that form complexes with KCNJ11 or KCNJ8 to create cardiac and smooth muscle-type channels 1. KCNJ11 forms the channel pore while ABCC9 is required for channel activation and regulation 1. ABCC9/KCNJ8-containing KATP channels modulate brain vascular smooth muscle cell differentiation and neurovascular coupling through regulation of intracellular calcium oscillations 2. Loss-of-function mutations in ABCC9 cause autosomal recessive intellectual disability and myopathy syndrome (AIMS), characterized by psychomotor delay, intellectual disability, microcephaly, white matter abnormalities, seizures, and muscle weakness 3. ABCC9 genetic variants are associated with dilated cardiomyopathy 4 and limbic-predominant age-related TDP-43 encephalopathy (LATE), a common dementia pathology affecting approximately 25% of elderly brains 5. ABCC9 is widely expressed across brain cell types including neurons, astrocytes, and vascular cells, serving as a metabolic sensor and regulator of the neurovascular unit 6. Knockout of ABCC9 increases doxorubicin-induced cardiotoxicity susceptibility in hiPSC-derived cardiomyocytes, suggesting roles in drug metabolism 7. Disease-associated polymorphisms function as expression quantitative trait loci, altering ABCC9 transcript levels and 3' UTR usage through microRNA targeting 8.

Sources cited
1
ABCC9 is a regulatory subunit of KATP channels forming complexes with KCNJ11; KCNJ11 forms the pore while ABCC9 is required for activation and regulation
PMID: 9831708
2
KCNJ8/ABCC9-containing KATP channels regulate brain vascular smooth muscle cell differentiation and neurovascular coupling through intracellular calcium modulation
PMID: 35588738
3
Loss-of-function ABCC9 mutations cause autosomal recessive ABCC9-related intellectual disability and myopathy syndrome with seizures, spasticity, and developmental abnormalities
PMID: 38217872
4
ABCC9 variants are associated with dilated cardiomyopathy and have high pathogenic potential in incidental genetic findings
PMID: 36129056
5
ABCC9 is identified as a genetic risk gene for limbic-predominant age-related TDP-43 encephalopathy (LATE), affecting approximately 25% of elderly brains
PMID: 31039256
6
ABCC9/SUR2 is expressed in multiple brain cell types including neurons, astrocytes, oligodendrocytes, and vascular cells; associated with hippocampal sclerosis of aging and serves as metabolic sensor
PMID: 26226329
7
ABCC9 knockout increases susceptibility to doxorubicin-induced cardiotoxicity in hiPSC-derived cardiomyocytes
PMID: 38510289
8
ABCC9 rs704180 polymorphism functions as an expression quantitative trait locus for hippocampal sclerosis of aging risk, affecting transcript levels through 3' UTR variation and microRNA regulation
PMID: 26115089
Disease Associationsβ“˜24
Hypertrichotic osteochondrodysplasia, Cantu typeOpen Targets
0.78Strong
hypertrichotic osteochondrodysplasia Cantu typeOpen Targets
0.77Strong
dilated cardiomyopathy 1OOpen Targets
0.75Strong
intellectual disability and myopathy syndromeOpen Targets
0.65Moderate
atrial fibrillation, familial, 12Open Targets
0.65Moderate
hypertensionOpen Targets
0.55Moderate
Abnormality of the skeletal systemOpen Targets
0.52Moderate
autosomal dominant dilated cardiomyopathyOpen Targets
0.51Moderate
hypotrichosisOpen Targets
0.50Moderate
Abnormality of the cardiovascular systemOpen Targets
0.47Moderate
neurodegenerative diseaseOpen Targets
0.45Moderate
dilated cardiomyopathyOpen Targets
0.42Moderate
familial atrial fibrillationOpen Targets
0.42Moderate
androgenetic alopeciaOpen Targets
0.41Moderate
cardiomyopathyOpen Targets
0.39Weak
alopeciaOpen Targets
0.37Weak
hypertrichosisOpen Targets
0.37Weak
Alzheimer diseaseOpen Targets
0.37Weak
osteochondrodysplasiaOpen Targets
0.37Weak
Parkinson diseaseOpen Targets
0.37Weak
Atrial fibrillation, familial, 12UniProt
Cardiomyopathy, dilated, 1OUniProt
Hypertrichotic osteochondrodysplasiaUniProt
Intellectual disability and myopathy syndromeUniProt
Pathogenic Variants102
NM_020297.4(ABCC9):c.2554C>T (p.Gln852Ter)Pathogenic
Cardiomyopathy|Dilated cardiomyopathy 1O
β˜…β˜…β˜†β˜†2025β†’ Residue 852
NM_020297.4(ABCC9):c.1057_1073dup (p.Phe359_Leu360insTerPhe)Pathogenic
Dilated cardiomyopathy 1O|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 359
NM_020297.4(ABCC9):c.3460C>T (p.Arg1154Trp)Pathogenic
Hypertrichotic osteochondrodysplasia Cantu type|Dilated cardiomyopathy 1O|15 conditions|not provided|ABCC9-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 1154
NM_020297.4(ABCC9):c.3347G>A (p.Arg1116His)Pathogenic
Hypertrichotic osteochondrodysplasia Cantu type|Dilated cardiomyopathy 1O
β˜…β˜…β˜†β˜†2025β†’ Residue 1116
NM_020297.4(ABCC9):c.2966G>A (p.Gly989Glu)Pathogenic
ABCC9-related disorder|Hypertrichotic osteochondrodysplasia Cantu type
β˜…β˜…β˜†β˜†2025β†’ Residue 989
NM_020297.4(ABCC9):c.565C>T (p.Arg189Ter)Pathogenic
Dilated cardiomyopathy 1O|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2025β†’ Residue 189
NM_020297.4(ABCC9):c.3461G>A (p.Arg1154Gln)Pathogenic
Hypertrichotic osteochondrodysplasia Cantu type|not provided|Dilated cardiomyopathy 1O|ABCC9-related disorder
β˜…β˜…β˜†β˜†2024β†’ Residue 1154
NM_020297.4(ABCC9):c.2506-1G>APathogenic
Intellectual disability and myopathy syndrome|Dilated cardiomyopathy 1O
β˜…β˜…β˜†β˜†2024
NM_020297.4(ABCC9):c.3346C>T (p.Arg1116Cys)Pathogenic
Hypertrichotic osteochondrodysplasia Cantu type|Dilated cardiomyopathy 1O|Kleefstra syndrome 1|not provided|Cardiovascular phenotype
β˜…β˜…β˜†β˜†2024β†’ Residue 1116
NM_020297.4(ABCC9):c.3796G>A (p.Val1266Met)Pathogenic
Dilated cardiomyopathy 1O|Inborn genetic diseases|not provided
β˜…β˜…β˜†β˜†2022β†’ Residue 1266
NM_020297.4(ABCC9):c.573+1G>TLikely pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2026
NM_020297.4(ABCC9):c.3849_3850del (p.Asn1283fs)Pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2026β†’ Residue 1283
NM_020297.4(ABCC9):c.3305del (p.Ile1102fs)Pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2025β†’ Residue 1102
NM_020297.4(ABCC9):c.1165-2A>GLikely pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2025
NM_020297.4(ABCC9):c.277del (p.Ser93fs)Pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2025β†’ Residue 93
NM_020297.4(ABCC9):c.4450-1G>ALikely pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2025
NM_020297.4(ABCC9):c.3252del (p.Phe1084fs)Pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2025β†’ Residue 1084
NM_020297.4(ABCC9):c.1164+1G>TLikely pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2025
NM_020297.4(ABCC9):c.285-1G>CLikely pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2025
NM_020297.4(ABCC9):c.351del (p.Ser118fs)Pathogenic
Dilated cardiomyopathy 1O
β˜…β˜†β˜†β˜†2025β†’ Residue 118
View on ClinVar β†—
Drug Targets2
MINOXIDILApproved
Sulfonylurea receptor 2, Kir6.2 opener
PINACIDILApproved
Sulfonylurea receptor 2, Kir6.2 opener
hypertension
Related Genes
RBM20Protein interaction81%SCN5AProtein interaction76%KCNJ8Protein interaction76%MYBPC3Protein interaction74%KCNJ11Protein interaction72%CSRP3Protein interaction72%
Tissue Expression6 tissues
Heart
100%
Liver
74%
Brain
27%
Ovary
23%
Lung
21%
Bone Marrow
0%
Gene Interaction Network
Click a node to explore
ABCC9RBM20SCN5AKCNJ8MYBPC3KCNJ11CSRP3
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt O60706
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.56Moderately Constrained
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.46 [0.38–0.56]
RankingsWhere ABCC9 stands among ~20K protein-coding genes
  • #5,587of 20,598
    Most Researched85
  • #616of 1,025
    FDA-Approved Drug Targets2
  • #759of 5,498
    Most Pathogenic Variants102 Β· top quartile
  • #3,607of 17,882
    Most Constrained (LOEUF)0.56 Β· top quartile
Genes detectedABCC9
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report.
PMID: 31039256
Brain Β· 2019
1.00
2
A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort.
PMID: 34602496
J Neuromuscul Dis Β· 2022
0.90
3
Determining the Likelihood of Disease Pathogenicity Among Incidentally Identified Genetic Variants in Rare Dilated Cardiomyopathy-Associated Genes.
PMID: 36129056
J Am Heart Assoc Β· 2022
0.80
4
KCNJ8/ABCC9-containing K-ATP channel modulates brain vascular smooth muscle development and neurovascular coupling.
PMID: 35588738
Dev Cell Β· 2022
0.70
5
Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes.
PMID: 38510289
JACC CardioOncol Β· 2024
0.60